Лучшие больницы для «Alpha-1-Antitrypsin Deficiency» в Дубай, ОАЭ

Alpha-1-Antitrypsin Deficiency (AATD) is an autosomal co-dominant genetic disorder caused by mutations in the SERPINA1 gene, most commonly the Pi*Z (Glu342Lys) allele. The resulting misfolded AAT protein is retained within hepatic endoplasmic reticulum, reducing circulating AAT to less than 11 µmol/L — far below the protective threshold of 35 µmol/L needed to neutralise neutrophil elastase in alveolar tissue. The unopposed elastase activity progressively destroys alveolar walls, producing panlobular emphysema with a characteristic basal predominance on high-resolution CT (HRCT). Concurrently, hepatic polymer accumulation triggers endoplasmic reticulum stress, chronic inflammation, and in susceptible patients, cirrhosis and hepatocellular carcinoma.

• CONFIRMED PHENOTYPE: Pi*ZZ, Pi*ZNull, Pi*SZ, or other severe AATD genotypes confirmed by serum AAT level (< 11 µmol/L or < 57 mg/dL by nephelometry) AND SERPINA1 genotyping or isoelectric focusing (IEF)
• PULMONARY ELIGIBILITY FOR AUGMENTATION: FEV1 15–65% predicted on spirometry; CT-documented emphysema (quantitative PD15 densitometry); non-smoker or smoking cessation confirmed ≥ 6 months; absence of IgA deficiency (risk of anaphylaxis to plasma products)
• LIVER DISEASE EVALUATION: All AATD patients require baseline liver assessment — serum LFTs, FibroScan® (liver stiffness ≥ 7 kPa warrants enhanced surveillance), abdominal ultrasound, and AFP for HCC screening in cirrhotic patients
• REQUIRED PRE-TREATMENT DIAGNOSTICS: Full pulmonary function tests (spirometry, body plethysmography, DLCO); HRCT thorax with quantitative densitometry; 6-minute walk test (6MWT) and SGRQ-C quality-of-life score; echocardiography (ECHO) to exclude pulmonary hypertension (RVSP > 40 mmHg modifies transplant candidacy); complete blood count, coagulation profile, serum protein electrophoresis; hepatitis B/C serology and HIV screening
• LIVER TRANSPLANT CANDIDACY (selected patients): MELD score ≥ 15 in AATD-related cirrhosis; Child-Pugh Class B or C; absence of active extrahepatic malignancy; psychosocial evaluation clearance
• +3 more

STANDARD AAT AUGMENTATION THERAPY (INTRAVENOUS): Weekly IV infusion of purified, pasteurised, human plasma-derived alpha-1-antitrypsin concentrate at 60 mg/kg body weight, administered over 15–30 minutes in an outpatient or day-care setting. This is the only FDA-approved, EMA-approved disease-modifying therapy for AATD-related emphysema. The RAPID and RAPID-OLE trials (the only double-blind, placebo-controlled studies in AATD) demonstrated a 34% reduction in annual CT lung density loss (PD15 endpoint) and a significant benefit in FEV1 decline in the treatment arm over 4 years. Hospitals in India and the UAE offer all four internationally approved concentrates through verified cold-chain pharmaceutical procurement, with dose preparation handled by clinical pharmacists under aseptic conditions.

OPTIMISED COPD PHARMACOTHERAPY (CONCURRENT): AATD-related emphysema is managed alongside standard GOLD-guideline COPD therapy: dual bronchodilation with LABA/LAMA combinations (indacaterol/glycopyrronium, tiotropium/olodaterol), triple therapy (fluticasone furoate/umeclidinium/vilanterol) for frequent exacerbators, and PDE4 inhibitor roflumilast for chronic bronchitis phenotype. Mucolytics, pulmonary rehabilitation (minimum 20 supervised sessions), and non-invasive ventilation (NIV/BiPAP) for hypercapnic respiratory failure are integrated into the treatment plan.

LIVER-DIRECTED THERAPIES (INVESTIGATIONAL/COMPASSIONATE USE): For patients with significant hepatic polymer accumulation and liver fibrosis, emerging therapies include: (1) Fazirsiran (ARO-AAT) — subcutaneous RNAi agent targeting SERPINA1 hepatic mRNA, achieving 80–90% reduction in hepatic Z-AAT polymer in Phase 2 AROAAT2002 trial; available at select trial sites in India (AIIMS, CMC Vellore) and UAE (Cleveland Clinic Abu Dhabi); (2) NTLA-2002 — in vivo CRISPR base-editing therapy in Phase 1/2; (3) Carbamazepine — an autophagy enhancer that reduces hepatic Z-AAT accumulation, used off-label in paediatric AATD liver disease; (4) Small-molecule correctors (similar to CFTR corrector strategy for cystic fibrosis) in preclinical-to-Phase-1 development.

SURGICAL OPTIONS: Bronchoscopic Lung Volume Reduction (BLVR): For patients with severe heterogeneous emphysema (FEV1 20–45% predicted, RV > 175%, absence of collateral ventilation on Chartis assessment), endobronchial valve (EBV) placement — using Zephyr valves (Pulmonx) — achieves lobar atelectasis and functional improvement in FEV1 (mean +14.6% in LIBERATE trial). Available at advanced bronchoscopy centres in India (Apollo Hospitals, Medanta, Fortis) and the UAE (Mediclinic City Hospital Dubai, Cleveland Clinic Abu Dhabi).

PHASE 1 — PRE-ARRIVAL PREPARATION (2–4 weeks before travel):

• GAF Healthcare coordinates remote review of available medical records: serum AAT level, SERPINA1 genotype report, spirometry, HRCT chest, and liver function tests
• Hospital specialist team confirms eligibility and designs a personalised treatment protocol
• GAF Healthcare assists with e-Medical Visa application for India (typically approved within 3 business days) or facilitates UAE entry clearance
• Patient receives a detailed Pre-Travel Medical Pack: list of required fasting tests, medication reconciliation instructions, and travel health advisory

PHASE 2 — ARRIVAL & DIAGNOSTIC CONFIRMATION (Days 1–3):